Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Express Scripts
McKinsey
QuintilesIMS
Fuji
Medtronic

Generated: April 23, 2019

DrugPatentWatch Database Preview

FORTEO Drug Profile

« Back to Dashboard

When do Forteo patents expire, and what generic alternatives are available?

Forteo is a drug marketed by Lilly and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in thirty-five countries.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the teriparatide recombinant human profile page.

Drug patent expirations by year for FORTEO
Generic Entry Opportunity Date for FORTEO
Generic Entry Date for FORTEO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for FORTEO
Synonyms for FORTEO
(1-34)-Human parathormone
(1-34)-Human parathyroid hormone
1-34-Human PTH
1-34-Parathormone (human)
10T9CSU89I
267417-73-2
289470-84-4
54651-28-4
64428-48-4
70212-84-9
99294-94-7 (acetate)
AKOS015994659
AKOS034831562
AN-7495
CHEBI:135983
FT-0656763
hPTH (1-34)
HPTH- (1-34)
HS-2025
HSDB 7367
Human parathyroid hormone (1-34)
Human PTH (1-34)
LS-183974
LS-187065
LS-187794
LY 333334
MN 10-T
MN 10T
MolPort-006-167-842
Parathar
Parathyroid hormone (1-34)
Parathyroid hormone (1-34) (human)
Parathyroid hormone peptide (1-34)
PTH 1-34
Teriparatida
Teriparatida [Spanish]
Teriparatide [USAN:INN:BAN:JAN]
Teriparatide [USAN]
Teriparatidum
Teriparatidum [Latin]
UNII-10T9CSU89I
ZT 034
ZT-034

US Patents and Regulatory Information for FORTEO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for FORTEO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for FORTEO
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 250 mcg/mL, 2.4 mL prefilled Pen ➤ Subscribe ➤ Try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
McKesson
Moodys
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.